ROMA (Risk of Ovarian Malignancy Algorithm)
| Label Mnemonic: | ROMA |
| Epic code: | LAB8570 |
| Downtime form: | A-1a Doctor/Provider Orders - Pathology Core and Specialty Care Nursery |
Commercial Mailout Laboratory
6240-8 RCP
356-8593
6240-8 RCP
356-8593
Specimen
Instructions:
Allow specimen to clot completely at room temperature.
Collection Medium:
 |
| Red top tube 5 mL (Clot Activator) |
Minimum:
Preferred Minimum: 1.5 mL serum
Absolute Minimum: 1.0 mL serum
Absolute Minimum: 1.0 mL serum
Rejection Criteria:
Hemolyzed specimens.
Testing Schedule:
Sunday-Saturday
Turn Around
Time:
Within 24 hours upon receipt at reference laboratory
Reference Range:
By Report
Interpretive Data:
The Risk of Ovarian Malignancy Algorithm (ROMA) combines the results of HE4, CA125, and menopausal status into a numerical score. If the patient is premenopausal, then a ROMA score of less than 1.14 is consistent with a low likelihood of finding a malignancy on surgery. If the patient is postmenopausal, then a ROMA score of less than 2.99 is consistent with a low likelihood of finding a malignancy on surgery.
ROMA is intended as an aid in assessing whether a premenopausal or postmenopausal woman who presenting with an ovarian adnexal mass is at high or low likelihood of having malignancy on surgery. ROMA is indicated for women who meet the following criteria: over age 18; ovarian adnexal mass present for which surgery is planned, and who has not yet referred to an oncologist. ROMA must be interpreted in conjunction with an independent clinical and radiological assessment. ROMA is not intended as a screening or stand-alone or tumor-monitoring assay. Tumor monitoring using HE4 and/or CA125 should be ordered separately.
ROMA is intended as an aid in assessing whether a premenopausal or postmenopausal woman who presenting with an ovarian adnexal mass is at high or low likelihood of having malignancy on surgery. ROMA is indicated for women who meet the following criteria: over age 18; ovarian adnexal mass present for which surgery is planned, and who has not yet referred to an oncologist. ROMA must be interpreted in conjunction with an independent clinical and radiological assessment. ROMA is not intended as a screening or stand-alone or tumor-monitoring assay. Tumor monitoring using HE4 and/or CA125 should be ordered separately.
Comments:
Ordering Recommendation - Assess cancer risk, particularly
epithelial cell ovarian cancer, in pre- and postmenopausal women who
present with an adnexal mass. Not intended as a screening, stand-
alone, or tumor-monitoring assay. Tumor monitoring using HE4 and/or CA
125 should be ordered separately.
Methodology:
Quantitative Electrochemiluminescent Immunoassay (ECLIA)
CPT Code:
86304, 86305